skip to primary navigationskip to content
 

Your liver on a microchip - a revolution in drug development

last modified Aug 18, 2017 09:36 AM
Funding for a cutting edge alternative to animal testing

ideaSpace West members, Stemnovate, and ANB Sensors Limited, both Cambridge based companies have been awarded $1 million Innovate UK funding to advance ‘Liver on a chip’ technology that will improve drug testing and help patients by increasing drug safety, effectiveness and potentially develop individually tailored medicine.

Dr. Ruchi Sharma, Stemnovate’s CEO, founder and lead on the project has long been concerned with limitations of animal testing for human drug development due to differences in species physiology. ‘It takes 10-15 years to launch a new drug with an average cost approximately 5 billion USD’ she says. ‘Drug failures and market withdrawal are hugely expensive and pose a great risk to patients. She stressed that one of the biggest challenges in drug discovery is figuring out which drug candidates are likely to harm the liver before testing them in humans. The ‘one size fits all,' approach currently dominant in drug development is suboptimal and often leads to drug failure putting patients at risk. ‘This is not surprising, after all there are multiple differences between humans which range from genetic make up, physiology, environment and lifestyle - all of which may interact and limit the drug’s success for individual patients’.

 

Dr. Ruchi Sharma

 Dr. Ruchi Sharma, Stemnovate’s CEO and Founder

The organ on chip technology has huge potential in tackling these problems. ‘Having the organ on a chip, instead of in the human or an animal, has multiple benefits. For starters, it is more ethical as the process does not involve animal or human testing. It is therefore also safer for the patients themselves. She explains that this new technology allows to identify problems early in medicine development process and can reduce development cost by as much as $30M per product launch. At the same time it also improves launch success rate by a quarter so the benefits are substantial.

Stemnovate and ANB Sensors Limited have teamed up with pharma to engineer a cost effective and flexible ‘liver on a chip’ system. It can faithfully replicate human liver biology by taking into account patients’ individual genetic backgrounds. This makes the technology more sensitive to individual patient’s circumstances, more accurate and more patient-friendly. According to Dr. Nathan Lawrence, CTO ANB Sensors Limited, ’The team’s aim is to integrate stem cell research and engineering to help patients. Developing such microphysiological models which are representative of human physiology is a big and important part of our project’.

Stemnovate’s co-founders, Professor David Hay and Dr. Adrian Fisher have a track record in this type of work. They have developed cutting edge stem cell and Microengineering platform technologies at University of Edinburgh and Cambridge and said, ’The liver on a chip project will be an exciting and unique opportunity for all involved: the patients, the healthcare system and the pharmaceutical industry’.

Mario Monshouwer, Senior Scientific Director, Janssen Pharmaceuticals, shares this enthusiasm and believes that new stem-cell based technologies such as ‘liver on a chip,' will transform medicine discovery in the very near future and we will live longer lives to see its great health benefits.

Ruchi was thrilled to learn that her team’s grant application was successful. The prestigious funding competition was conducted by UK’s innovation agency, Innovate UK to address technical or commercial challenges in health and life sciences. She is now looking forward to leading this very promising research programme towards a healthier future for us all.

For further information contact:

ruchi.sharma@stemnovate.co.uk

or info@stemnovate.co.uk

 

page2image5232

RSS Feed Latest news

LESSONS FROM A FOUNDER: Taking Your Technology to Market with Scott White from PragmatIC

Mar 14, 2019

Scott White, ideaSpace alumni and serial entrepreneur is CEO of PragmatIC. PragmatIC produces sheets of flexible integrated circuits (FlexICs), extending the reach of electronics into markets unfeasible for silicon for reasons of form factor and/or cost. Printed electronics is one of the world’s fastest growing technologies, representing enormous potential in interconnected devices. In recognition of British Science Week, we spoke to Scott about the company’s journey from a technology-based concept to the production of commercial products, and asked his advice about taking a new technology to market.

LESSONS FROM A FOUNDER: Basics of Building a Business - IP with Christian Bunke

Feb 28, 2019

With the next B3 event coming up in the next few weeks, we thought we’d take a look back at some previous B3s and learn more about what it takes to build a business. But first – a bit about B3. Our Basics of Building a Business event, or B3, is hosted by a Founder who has successfully scaled their business. They invite the three people who proved vital in helping them along the way to share what they did, how they did it and so much more on what you need to do to go from start up to scale up. Late last year Adam Durant, CEO of Satavia and alumni of ideaSpace, was our guest founder for the evening and invited along Christian Bunke of Basck - an IP Firm focused on working with startups. Here’s what he had to say…

Spotlight on Mursla

Feb 03, 2019

Cancer is one of the most challenging global issues an entrepreneur could choose to tackle. But Pierre Arsène and Victor Serdio are doing just that with their company Mursla. Based at ideaSpace West, Mursla is developing a breakthrough technology for early cancer detection using liquid biopsies, offering a less invasive and more responsive approach to diagnosis, treatment and cure. To mark World Cancer Day on the 4th February, we asked Pierre to explain more about Mursla and the bold ideas and enthusiasm driving this bright company.

LESSONS FROM A FOUNDER: What's Your 2019 Startup Goal?

Jan 30, 2019

For many of us, a new year often starts with an optimistic resolution to change – join the gym, write a book, travel perhaps. But if you’re running a startup, January is a great time to assess your company’s development and set fresh goals for the coming year. We asked four founders at ideaSpace to reflect on progress and share their area of focus for 2019.

GeoSpock Lands £10 Million in Additional Funding 

Jan 09, 2019

ideaSpace alumni and extreme data specialists, GeoSpock, have secured an extra  £10 million in funding. The latest round was led by Cambridge Innovation Capital (CIC) jointly with Parkwalk Advisors and Japanese firms Global Brain and 31Ventures. Japanese data tech company KDDI Supership joined as a strategic investor. Investment was also secured from existing investor, Jonathan Milner.

View all news